Share the Video:

The Light of Psychedelics in a Dark World

Rick Doblin

38 years after founding the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) on April 8, 1986, Rick Doblin, Ph.D., will explore nearly four decades of psychedelic triumphs and challenges. In December 2023, Lykos Therapeutics (formerly MAPS Public Benefit Corporation) submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for MDMA-assisted therapy for posttraumatic stress disorder (PTSD). Rick will discuss MAPS’ path toward mass mental health by means of public education, drug policy reform, and global humanitarian projects.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Pioneers of MDMA Therapy: Reflections on 20+ Years of MDMA Therapy and Research

MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.

Keren Tzarfaty, Michael Mithoefer, Julie Holland

PS2023 MDMA Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research

Preview Scene from Prescription X: The Rick Doblin and MAPS Documentary (Work in Progress)

"Prescription X: The Rick Doblin Story" documents Dr. Rick Doblin's quest with MAPS to legalize MDMA and psychedelics for therapy, culminating in a revealing film by Nirvan and Dream Mullick.

Nirvan Mullick, Dream Mullick

PS2023 MDMA Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science

Priorities for the next generation of psychedelic science

NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study

Joshua A Gordon

PS2023 Policy and Advocacy Psychedelic Science Psychedelic-AT Public Benefit Research

Visionary Women: Transforming Psychedelic Medicine

Vicky Dulai of Compassion For Addiction moderates a discussion with Amy Emerson of MAPS Public Benefit Corporation and Rachel Yehuda of Icahn School of Medicine on leadership in the psychedelic

Rachel Yehuda

PS2023 Business Policy and Advocacy Psychedelic Science Research Research and Science

The state of the psychedelic sector

Hardman provides a quick overview of the emerging psychedelic sector, covering financial, research, and policy landscapes with data visuals. He also explores unanswered questions about the sector's future.

Josh Hardman

PS2023 Harm Reduction Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Proactive harm reduction by preparing set, setting, and substance

Harm reduction superheroes delve into risk mitigation and benefit maximization, exploring mindset, setting, and substances for safer drug experiences and systemic change.

Mitchell Gomez, Phoenix aka Mohawk Greene

PS2023 Harm Reduction Integration Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research

Responding to Crises and Calls with Psychedelic Harm Reduction

Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case

Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Building momentum for new state policy approaches

Expansion of psychedelic policy in the US includes decriminalization, adult use regulations, and increased research funding. Elected state lawmakers discuss challenges, opportunities, and lessons from proposed psychedelic legislation.

Rep La Shawn Ford (IL), Rep Alex Dominguez (TX), Tamar Todd

PS2023 Harm Reduction Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Giving and growth: the role of philanthropic funding in the psychedelic sector

Philanthropy and investors can support crucial psychedelic research and initiatives beyond commercial interests to shape the field and promote equity and social value in the psychedelic economy.

Sandy Samberg

The Light of Psychedelics in a Dark World

Become a MAPS Member with a monthly donation

Related Videos